Denali Therapeutics Inc. DNLI Business Segments — Total collaboration revenue

Similar metrics at other companies

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

TVTXLicense and collaboration revenue — Total Revenue

$2.71M-54.1%

RCUSOther collaboration — Total revenues

$5M-37.5%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

EXELCollaboration — Total revenues

$55.84M+32.4%

EXELCollaboration services revenues — Total revenues

-$3.96M-211%

Questions, answered.

What is Denali Therapeutics Inc.'s business segments — total collaboration revenue?

Denali Therapeutics Inc. (DNLI) reported business segments — total collaboration revenue of $0 in Q4 2025.

What is the long-term trend for Denali Therapeutics Inc.'s business segments — total collaboration revenue?

Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — total collaboration revenue has grown at a -100.0% compound annual growth rate (CAGR), from $108.46M to $0.

What does business segments — total collaboration revenue mean?

This metric captures the total revenue recognized from strategic partnerships, licensing agreements, and collaborative research arrangements within the therapeutics segment. It reflects the company's ability to monetize its intellectual property and research pipeline through external industry alliances. Fluctuations in this metric often indicate the timing of milestone achievements or the initiation of new joint development programs.